Posted in | News | Nanomedicine

NanoViricides and UCSF Sign Agreement for Anti-HIV Drug Candidate Testing

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced that it has signed a Research Agreement with the University of California, San Francisco (UCSF) for testing of its anti-HIV drug candidates.

Cheryl Stoddart, PhD, Assistant Professor in the UCSF Division of Experimental Medicine, will be the Principal Investigator.

Dr. Stoddart is a recognized investigator in preclinical studies of anti-HIV compounds using the standard SCID-hu Thy/Liv humanized mouse model. In particular, she is well known for her work in validating that this mouse model is capable of accurately predicting clinical antiviral efficacy in humans. The National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), has recognized UCSF as an important site for anti-HIV drug screening studies.

Dr. Stoddart’s in-vivo testing of anti-HIV nanoviricides will complement the Company’s previously announced in-vitro anti-HIV testing that is currently underway at the Southern Research Institute in Frederick, MD.

The Company has previously performed anti-HIV nanoviricides testing in vivo at KARD Scientific, Beverly, MA. In these studies, several nanoviricide drug candidates were shown to have equal effectiveness in terms of multiple parameters to a clinical anti-HIV HAART three-drug cocktail. The HAART cocktail drugs were administered at a much greater total dosage (4,100 mg/kg of HAART) than the nanoviricides (only 150mg/kg of the nanoviricides). This study evaluated several parameters including the reduction of HIV viral load, improvement in CD4+/CD8+ double-positive human T cells, and HIV particle count inside human T cells in the transplant, among others. The best nanoviricide drug candidate was greater than 25X (2,500%) superior to the HAART drug cocktail based on the amount of drug that produced comparable or superior effect. If these results are indicative of clinical response in humans, the Company believes that HIVCide™, its lead drug candidate against HIV, may constitute a “functional cure” for HIV/AIDS, either by itself, or in combination with existing therapies.

“We are very interested to find out how our prior results compare to the standardized studies in Dr. Stoddart’s lab,” said Anil R. Diwan, PhD, President of the Company.

Source: http://www.nanoviricides.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoViricides, Inc. (2019, February 13). NanoViricides and UCSF Sign Agreement for Anti-HIV Drug Candidate Testing. AZoNano. Retrieved on December 09, 2024 from https://www.azonano.com/news.aspx?newsID=17570.

  • MLA

    NanoViricides, Inc. "NanoViricides and UCSF Sign Agreement for Anti-HIV Drug Candidate Testing". AZoNano. 09 December 2024. <https://www.azonano.com/news.aspx?newsID=17570>.

  • Chicago

    NanoViricides, Inc. "NanoViricides and UCSF Sign Agreement for Anti-HIV Drug Candidate Testing". AZoNano. https://www.azonano.com/news.aspx?newsID=17570. (accessed December 09, 2024).

  • Harvard

    NanoViricides, Inc. 2019. NanoViricides and UCSF Sign Agreement for Anti-HIV Drug Candidate Testing. AZoNano, viewed 09 December 2024, https://www.azonano.com/news.aspx?newsID=17570.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.